Johnson & Johnson's COVID-19 has showed positive results in South Africa, the co-head of a trial, Glenda Gray, told reporters on Friday. Giving information, South African official Gray said that, as a research, about 4,77,234 health workers of the country have been vaccinated with J&J for the month of February.
She further said that, one dose of the vaccine is effective from 91 percent to 96.2 percent against death. At the same time, it is 67% effective against beta coronavirus and 71% effective against delta variants. South Africa's health regulators approved the use of the J&J vaccines in April.
On the other hand, J&J on Friday said it has applied for Emergency Use Authorization (EUA) of its single-dose coronavirus vaccine in India. Earlier on Monday, the company had said that it is looking forward to the discussion with the Government of India.
In a statement, a Johnson & Johnson India spokesperson said, "On August 5, 2021 Johnson & Johnson Pvt Ltd applied for EUA of its single-dose COVID-19 vaccine to the government of India. This is an important milestone that paves the way for bringing the company's single-dose vaccine to the people of India. And the rest of the world, through a collaboration with Biological E Limited. Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson COVID-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the COVAX Facility."
Also Read:
Like and Follow us on :
